Featuring an interview with Dr Brian Slomovitz, including the following topics: Comparative efficacy and safety of commercially available PARP inhibitors for ovarian cancer (OC) (0:00) Patient- and disease-specific considerations in the selection and sequencing of treatment for OC with BRCA mutations (11:39) Mechanism of action of mirvetuximab soravtansine; recent efficacy and safety data with mirvetuximab for platinum-resistant OC from the SORAYA trial (15:13) Potential integration of mirvetuximab soravtansine into the treatment algorithm for platinum-resistant OC; emerging data with niraparib/dostarlimab and adavosertib for OC (20:23) Ongoing clinical trials evaluating tumor treating fields and upifitamab rilsodotin for OC (24:57) Recent follow-up data with pembrolizumab/bevacizumab/chemotherapy for metastatic cervical cancer (CC) from the KEYNOTE-826 trial (27:30) Efficacy and safety data with lenvatinib/pembrolizumab from the KEYNOTE-775 trial for endometrial cancer (EC); benefit of lenvatinib/pembrolizumab in subsequent lines of therapy (32:13) Updated data with dostarlimab for microsatellite instability (MSI)-high EC; ongoing clinical trials evaluating immunotherapy versus chemotherapy alone for MSI-high EC (35:47) HER2-low data with T-DXd for breast cancer and its potential role in therapy for EC; emerging role of mTOR inhibitors; ongoing investigations and unmet needs in OC, CC and EC (40:01) CME information and select publications

Ver todos los episodios